M55 Stock Overview A biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
MacroGenics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for MacroGenics Historical stock prices Current Share Price US$3.18 52 Week High US$19.80 52 Week Low US$2.63 Beta 2.03 1 Month Change 0.32% 3 Month Change -1.43% 1 Year Change -65.27% 3 Year Change -76.82% 5 Year Change -68.84% Change since IPO -82.73%
Recent News & Updates
Third quarter 2024 earnings released: EPS: US$0.90 (vs US$0.28 in 3Q 2023) Nov 06 Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year
MacroGenics, Inc. Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 Sep 16
Second quarter 2024 earnings released: US$0.89 loss per share (vs US$0.93 profit in 2Q 2023) Aug 07
Macrogenics Provides Vobramitamab Duocarmazine Update Aug 01
MacroGenics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31 See more updates
Third quarter 2024 earnings released: EPS: US$0.90 (vs US$0.28 in 3Q 2023) Nov 06 Scott Koenig Intends to Step Down as Chief Executive Officer of MacroGenics, Inc., Early Next Year
MacroGenics, Inc. Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 Sep 16
Second quarter 2024 earnings released: US$0.89 loss per share (vs US$0.93 profit in 2Q 2023) Aug 07
Macrogenics Provides Vobramitamab Duocarmazine Update Aug 01
MacroGenics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31 Block & Leviton Files Lawsuit Against MacroGenics, Inc Jul 30
New major risk - Financial position Jul 01
First quarter 2024 earnings released: US$0.84 loss per share (vs US$0.61 loss in 1Q 2023) May 10
MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures Apr 04
Full year 2023 earnings released: US$0.15 loss per share (vs US$1.95 loss in FY 2022) Mar 08
Investor sentiment improves as stock rises 15% Mar 05
MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Feb 28
Investor sentiment improves as stock rises 20% Jan 26
Investor sentiment improves as stock rises 16% Dec 07
Investor sentiment improves as stock rises 21% Nov 13
Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.40 loss in 3Q 2022) Nov 07
MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Nov 01
Insider recently bought €67k worth of stock Sep 03
Investor sentiment deteriorates as stock falls 16% Aug 17
New major risk - Share price stability Aug 11
Second quarter 2023 earnings released: EPS: US$0.93 (vs US$0.67 loss in 2Q 2022) Aug 10
MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 01
First quarter 2023 earnings released: US$0.61 loss per share (vs US$1.08 loss in 1Q 2022) May 11
MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023 May 05
Full year 2022 earnings released: US$1.95 loss per share (vs US$3.37 loss in FY 2021) Mar 17 Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients Feb 15
MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors Jan 05
Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director Dec 24
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab Nov 19
Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.86 loss in 3Q 2021) Nov 05
MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 27
Second quarter 2022 earnings released: US$0.67 loss per share (vs US$0.67 loss in 2Q 2021) Aug 09
MacroGenics, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
MacroGenics, Inc. Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer Jul 09
Senior VP recently bought €95k worth of stock Jun 18
MacroGenics, Inc. Announces Management Changes May 24
First quarter 2022 earnings released: US$1.08 loss per share (vs US$0.90 loss in 1Q 2021) May 05
Insufficient new directors Apr 27
MacroGenics, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 26
MacroGenics, Inc., Annual General Meeting, May 19, 2022 Apr 09
MacroGenics, Inc. Announces Promotion of Eric Risser to Chief Operating Officer Mar 01
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 26
MacroGenics, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 15
Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.66 loss in 3Q 2020) Nov 04
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer Sep 08
Second quarter 2021 earnings released: US$0.67 loss per share (vs US$0.94 loss in 2Q 2020) Jul 31
Insufficient new directors Jul 27
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting May 21
First quarter 2021 earnings released: US$0.90 loss per share (vs US$0.91 loss in 1Q 2020) May 01
Full year 2020 earnings released: US$2.47 loss per share (vs US$3.16 loss in FY 2019) Feb 28
Revenue beats expectations Feb 28
MacroGenics, Inc. Provides Update Proprietary Programs Feb 26
New 90-day low: €16.00 Feb 19
MacroGenics, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
MacroGenics, Inc. Names Federica O’Brien to its Board of Directors Feb 13
New 90-day low: €16.30 Jan 29
Macrogenics, Inc. Announces the Publication of Results from the Sophia Trial of Margenza Jan 26
Macrogenics, Inc. Announces Research Collaboration and Global License Agreement to Develop Preclinical Bispecific Molecule with Janssen Biotech, Inc Dec 20
MacroGenics, Inc. Announces FDA Approval of MARGENZA for Patients with Pretreated Metastatic HER2-Positive Breast Cancer Dec 18
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia At the 2020 ASH Annual Meeting Dec 09
MacroGenics, Inc. and EVERSANA Announces Agreement to Support the Potential Launch and Commercialization of Margetuximab Dec 01
Revenue beats expectations Nov 06
Third quarter 2020 earnings released: US$0.66 loss per share Nov 06
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020 Nov 06
MacroGenics, Inc. to Report Q3, 2020 Results on Nov 04, 2020 Oct 29
MacroGenics, Inc. Enters into A Commercial Supply Agreement with Incyte Corporation Oct 18
MacroGenics Announces Flotetuzumab Publication in Blood Advances Oct 17
New 90-day low: €20.80 Oct 16
New 90-day low: €21.00 Sep 25
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood Sep 24 MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
MacroGenics, Inc. Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020 Sep 21
MacroGenics, Inc. announced that it has received funding from Havencrest Capital Management, LLC Aug 13
MacroGenics, Inc. to Report Q2, 2020 Results on Jul 30, 2020 Jul 24 MacroGenics, Inc.(NasdaqGS:MGNX) dropped from Russell Microcap Index
MacroGenics, Inc.(NasdaqGS:MGNX) dropped from Russell Microcap Value Index Jul 03 Shareholder Returns M55 DE Biotechs DE Market 7D 3.1% 2.5% -0.4% 1Y -65.3% -10.2% 7.9%
See full shareholder returns
Return vs Market: M55 underperformed the German Market which returned 7.9% over the past year.
Price Volatility Is M55's price volatile compared to industry and market? M55 volatility M55 Average Weekly Movement 9.7% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: M55's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: M55's weekly volatility has decreased from 15% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
Show more MacroGenics, Inc. Fundamentals Summary How do MacroGenics's earnings and revenue compare to its market cap? M55 fundamental statistics Market cap €210.73m Earnings (TTM ) -€94.73m Revenue (TTM ) €137.15m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) M55 income statement (TTM ) Revenue US$141.33m Cost of Revenue US$192.63m Gross Profit -US$51.30m Other Expenses US$46.32m Earnings -US$97.62m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.56 Gross Margin -36.30% Net Profit Margin -69.07% Debt/Equity Ratio 0%
How did M55 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 18:09 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources MacroGenics, Inc. is covered by 25 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Lawson Barclays Etzer Darout BMO Capital Markets Equity Research Stephen V. Byrne BofA Global Research
Show 22 more analysts 
